As of August 27, 2026, there is no FDA-approved novel-drug breakthrough specifically for blackheads; the main change is nonprescription access to Differin Epiduo Acne Gel. Blackheads—clogged pores that remain open at the skin surface—still require consistent treatment, while an experimental pill and newer laser data remain developments to watch. The update changes what some people can obtain without a prescription, not how quickly acne clears. It also brings practical safety reminders about benzoyl peroxide and delays planned changes to isotretinoin monitoring.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changed at the pharmacy?
- How should the new OTC treatment be used?
- What does established evidence still support?
- What should readers know about benzoyl peroxide safety?
- What is next for oral acne treatment?
- What else should readers watch?
What changed at the pharmacy?
The FDA's 2026 novel-drug approvals table lists no new acne treatment through August 27. Claims of an FDA-approved "blackhead breakthrough" therefore overstate what the agency has documented. The meaningful access change came May 22.
The FDA approved Differin Epiduo Acne Gel, containing adapalene 0.1% and benzoyl peroxide 2.5%, for nonprescription acne treatment in adults and children aged 12 and older, according to the agency's prescription-to-nonprescription switch list. Adapalene is a topical retinoid that targets clogged pores and inflammation. Benzoyl peroxide adds antimicrobial action, making the combination relevant when blackheads occur alongside red, inflamed acne.
How should the new OTC treatment be used?
The FDA label directs users to apply a thin layer once daily across the entire affected area. That means treating an acne-prone zone rather than placing extra gel on individual blackheads.
The label also says results may take up to three months and warns that excessive use can worsen irritation. More product or more frequent applications do not create a faster treatment, as the FDA-approved instructions make clear. The practical checklist is short:.
- Confirm the user is at least 12 years old.
- Apply a thin layer once daily.
- Cover the affected area, not just visible spots.
- Allow up to three months for results.
- Do not increase use in response to slow improvement.
What does established evidence still support?
The American Academy of Dermatology's current guideline strongly recommends topical retinoids because they unclog pores and reduce inflammation. That keeps retinoid-based treatment central for blackheads despite attention around devices and experimental drugs. The guideline also advises combining benzoyl peroxide with topical or oral antibiotics to reduce antibiotic resistance.
However, it finds insufficient evidence to broadly recommend chemical peels, laser or light devices, microneedling, diet changes, or alternative therapies. For readers choosing between well-marketed options, that distinction matters. A treatment can be available or promising without having enough evidence for broad guideline support.
What should readers know about benzoyl peroxide safety?
FDA testing found that more than 90% of 95 tested benzoyl peroxide acne products contained undetectable or extremely low benzene. Six products had elevated levels and prompted retail-level recalls.
The agency characterized the cancer risk from the identified exposure as very low. Its practical advice is to check product expiration dates, rather than assume every benzoyl peroxide cleanser or gel is unsafe.
What is next for oral acne treatment?
On August 13, Sagimet Biosciences reported that the FDA cleared its investigational new drug application for a U.S. Phase 3 trial of denifanstat. The oral drug inhibits fatty acid synthase and is being studied for moderate-to-severe acne.
The planned 800-patient study includes adolescents ages 12 to 17. It will assess inflammatory and non-inflammatory lesion counts after 12 weeks, according to Sagimet's trial announcement. Denifanstat is not an approved acne medicine. The company's trial-start and dosing timelines are forward-looking, so the useful milestones are trial registration, completed results, and any eventual FDA review—not the announcement alone.
What else should readers watch?
FDA delayed planned iPLEDGE isotretinoin risk-management changes from August 8 to November 15, 2026. The agency said the delay allows system testing intended to avoid treatment interruptions. Once implemented, the changes permit home pregnancy testing during and after treatment when the prescriber allows it.
Pregnancy tests before treatment must still occur in a medical setting. A July 2026 retrospective study of a 1726-nanometer, sebum-selective laser reported that 75% of real-world patients had clear or almost-clear skin at two years. Because the analysis was retrospective and conducted after FDA clearance, it does not establish that the procedure should replace guideline-backed topical care.